Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Charles Warden
AddedMar 31, 2024
UpdatedMay 31, 2026
Charles Warden

Charles Warden

Board Member, Ocular Therapeutix

Crunchbase

Charles Warden's Career

Ocular Therapeutix
Ocular Therapeutix

Bedford, MA, US

Board Member· Board
Celula
Celula

San Diego, CA, US

Board Member· Board
Halscion
Halscion

Duluth, GA, US

Board Member· Board
AcuFocus
AcuFocus

Irvine, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Charles Warden's Career

Ocular Therapeutix
Ocular Therapeutix
Public$386.5M2742006Bedford, MA, US
Board Member· Board

Leadership at Ocular Therapeutix

Antony MattessichAntony MattessichBoard Member
Merilee RainesMerilee RainesBoard Member
Amarpreet SawhneyAmarpreet SawhneyCo-Founder
Fred KhosraviFred KhosraviCo-Founder
Leslie J WilliamsLeslie J WilliamsBoard Member
Richard L LindstromRichard L LindstromBoard Member

Similar to Ocular Therapeutix

Ocular ScienceOcular ScienceManhattan Beach, CA, USEye Care ProductsOcular ScienceManhattan Beach, CA, US

Ocular Science®: A leading biotech firm innovating affordable eye care solutions.

Seed · $175.1k46
Hyperion DeFiHyperion DeFiNew York City, NY, USTherapeuticsest. 2014Hyperion DeFiNew York City, NY, US · est. 2014

Eyenovia, Inc.: A NASDAQ-listed biopharmaceutical firm innovating advanced ophthalmic therapeutics.

Public · $75.1M41
OcuCure TherapeuticsOcuCure TherapeuticsRoanoke, VA, USEye Drops, Pharmaceuticalsest. 2005OcuCure TherapeuticsRoanoke, VA, US · est. 2005

OcuCure Therapeutics: Developing innovative eye drops for age-related and diabetic eye diseases since 2005.

Public · $3.3M8
EyeCyteEyeCyteLos Angeles, CA, USTherapeuticsest. 2005EyeCyteLos Angeles, CA, US · est. 2005

EyeCyte: Developing novel therapeutics for neovascular and degenerative retinal diseases.

Series A · $3M5
Celula
Celula
Series A$10M302005San Diego, CA, US
Board Member· Board

Leadership at Celula

Heiner DreismannHeiner DreismannBoard Member
Haichuan ZhangHaichuan ZhangFounder
Jordan KramerJordan KramerBoard Member
Drew SenyeiDrew SenyeiBoard Member

Similar to Celula

Cellia ScienceCellia ScienceFayetteville, AR, USBlood Cell Assaysest. 2021Cellia ScienceFayetteville, AR, US · est. 2021

Cellia Science: Rapid, accurate, point-of-care blood cell assays with results in minutes.

Angel · $300k2
Sampling HumanSampling HumanBerkeley, CA, USHealthTechest. 2016Sampling HumanBerkeley, CA, US · est. 2016

Sampling Human: Advancing health tech by linking decisions to cellular effects for precise diagnoses.

Seed · $3.7M37
IncellDxIncellDxMenlo Park, CA, USMedical Instrumentsest. 2009IncellDxMenlo Park, CA, US · est. 2009

IncellDx, a California-based medical firm, develops and distributes diagnostic instruments for life-threatening diseases globally.

Series A · $9M26
Celerus DiagnosticsCelerus DiagnosticsCarpinteria, CA, USDiagnostics, Healthcareest. 2004Celerus DiagnosticsCarpinteria, CA, US · est. 2004

Celerus Diagnostics: A comprehensive healthcare provider since 2008.

Series D · $16.7M11
Halscion
Halscion
Series B$13.8M92005Duluth, GA, US
Board Member· Board

Leadership at Halscion

Ronald YamamotoRonald YamamotoBoard Member
Tom WeldonTom WeldonCo-Founder
Anthony LandoAnthony LandoBoard Member
Kathleen M. BeauchampKathleen M. BeauchampBoard Member

Similar to Halscion

Halcyon BiomedicalHalcyon BiomedicalFriendswood, TX, USMedical Devicesest. 2010Halcyon BiomedicalFriendswood, TX, US · est. 2010

US-based Halcyon Biomedical innovates medical devices for purifying stored blood, established in 2013.

Pre-Seed · $1.1M1
HealionicsHealionicsSeattle, WA, USMedical Devicesest. 2007HealionicsSeattle, WA, US · est. 2007

Seattle-based Healionics offers innovative vascular grafts for enhanced dialysis patient care.

Series A · $19.4M11
Halo Medical TechnologiesHalo Medical TechnologiesWilmington, DE, USMedical Devicesest. 2012Halo Medical TechnologiesWilmington, DE, US · est. 2012

HALO Medical Technologies: Providing advanced diagnostic ultrasound products and accessories since 2012.

Seed · $210k6
Hs PharmaceuticalsHs PharmaceuticalsGreenville, SC, USDermatological Products, Wound Careest. 2007Hs PharmaceuticalsGreenville, SC, US · est. 2007

HS Pharmaceuticals: Crafting dermatological solutions for wounds and infections since 2007.

Series A · $8.6M8
AcuFocus
AcuFocus
Acquired$241.6M02001Irvine, CA, US
Board Member· Board

Leadership at AcuFocus

Charles LarsenCharles LarsenFounder
Greg MaddenGreg MaddenBoard Member
Conrad WangConrad WangBoard Member
William LinkWilliam LinkBoard Member
James GarveyJames GarveyBoard Member
Arjun AroraArjun AroraBoard Member

Charles Warden's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Charles Warden

Scott MawScott MawBoard Member · AlconC. Raymond LarkinC. Raymond LarkinBoard Member · Reva MedicalGrant AllenGrant AllenCo-Founder · ABB Technology Ventures